TP 9201
Latest Information Update: 23 Aug 2002
At a glance
- Originator Telios Pharmaceuticals
- Class Antiplatelets; Ischaemic heart disorder therapies; Peptides; Vascular disorder therapies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Reperfusion injury; Stroke; Thrombosis; Unstable angina pectoris; Vascular restenosis
Most Recent Events
- 25 Nov 1998 Phase-I clinical trials for Reperfusion injury in USA (Unknown route)
- 25 Nov 1998 Phase-I clinical trials for Unstable angina pectoris in USA (Unknown route)
- 25 Nov 1998 Phase-I clinical trials for Vascular restenosis in USA (Unknown route)